Collaboration Agreements - Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue (Detail) $ in Thousands	Mar. 31, 2016 USD ($)
Astellas Agreement [Member] \| Japan [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	$ 44,321
Deferred Revenue	27
Total Consideration	44,348
Astellas Agreement [Member] \| Japan [Member] \| License [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	42,320
Deferred Revenue	0
Total Consideration	42,320
Astellas Agreement [Member] \| Japan [Member] \| When and if available compounds [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	15
Deferred Revenue	27
Total Consideration	42
Astellas Agreement [Member] \| Japan [Member] \| Manufacturing-clinical supplies [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	1,969
Deferred Revenue	0
Total Consideration	1,969
Astellas Agreement [Member] \| Japan [Member] \| Committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	17
Deferred Revenue	0
Total Consideration	17
Astellas Agreement [Member] \| Europe [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	447,278
Deferred Revenue	429
Total Consideration	447,707
Astellas Agreement [Member] \| Europe [Member] \| License [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	404,554
Deferred Revenue	0
Total Consideration	404,554
Astellas Agreement [Member] \| Europe [Member] \| When and if available compounds [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	343
Deferred Revenue	427
Total Consideration	770
Astellas Agreement [Member] \| Europe [Member] \| Manufacturing-clinical supplies [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	9,690
Deferred Revenue	0
Total Consideration	9,690
Astellas Agreement [Member] \| Europe [Member] \| Committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	278
Deferred Revenue	2
Total Consideration	280
Astellas Agreement [Member] \| Europe [Member] \| Development services-in progress [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	32,413
Deferred Revenue	0
Total Consideration	32,413
AstraZeneca Agreements [Member] \| U.S./RoW [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	364,769
Deferred Revenue	97,593
Total Consideration	462,362
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| License [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	306,191
Deferred Revenue	0
Total Consideration	306,191
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Manufacturing-clinical supplies [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	261
Deferred Revenue	57
Total Consideration	318
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| Co-development, information sharing & committee services [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	58,317
Deferred Revenue	34,775
Total Consideration	93,092
AstraZeneca Agreements [Member] \| U.S./RoW [Member] \| China-single unit of accounting [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Cumulative Revenue	0
Deferred Revenue	62,761
Total Consideration	$ 62,761

The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.

No definition available.

+ Details

Name:	fgen_CashConsiderationReceivedUnderCollaborationAgreement
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total amount of revenue recognized for license and collaboration services under the collaboration agreement as of a given date.

+ References

No definition available.

+ Details

Name:	fgen_CumulativeRevenueLicenseAndCollaborationServicesRevenueRecognized
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstellasCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_WhenAndIfAvailableCompoundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_ManufacturingClinicalSuppliesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_CommitteeServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_DevelopmentServicesInProgressMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_CoDevelopmentInformationSharingAndCommitteeServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=fgen_ChinaSingleUnitOfAccountingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: